LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

LLY

1,076.26

+0.08%↑

JNJ

206.89

+0.14%↑

ABBV

229.02

+0.55%↑

UNH

328.59

-0.44%↓

AZN

92.61

-0.13%↓

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

585.51 -1.9

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

585.33

Максимум

595.58

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
EPS	-4.956
Марж на печалбата	-39.75
Служители	528
EBITDA	-75M -114M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-5.9% downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.2B 13B
Предишно отваряне	587.41
Предишно затваряне	585.51

Настроения в новините

By Acuity

40%

60%

139 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.11.2025 г., 15:29 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

30.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over U.S. Economy, Japan Earnings -- Market Talk

30.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Australian Equities Typically Rise in Year Before Rate Hikes Start -- Market Talk

30.11.2025 г., 07:30 ч. UTC

Придобивния, сливания и поглъщания

Strategy Insiders Kept Buying Preferred Stock as Bitcoin Price Slid -- Barrons.com

28.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 19:59 ч. UTC

Пазарно говорене

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28.11.2025 г., 19:47 ч. UTC

Пазарно говорене

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 17:48 ч. UTC

Пазарно говорене

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28.11.2025 г., 15:51 ч. UTC

Пазарно говорене

Canada Household Spending Edges Lower -- Market Talk

28.11.2025 г., 15:33 ч. UTC

Пазарно говорене

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28.11.2025 г., 15:21 ч. UTC

Пазарно говорене

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28.11.2025 г., 15:13 ч. UTC

Пазарно говорене

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28.11.2025 г., 14:51 ч. UTC

Пазарно говорене

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28.11.2025 г., 14:41 ч. UTC

Пазарно говорене

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28.11.2025 г., 14:37 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28.11.2025 г., 14:20 ч. UTC

Пазарно говорене

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28.11.2025 г., 14:10 ч. UTC

Пазарно говорене

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

-5.9% надолу

12-месечна прогноза

Среден 561.73 USD -5.9%

Висок 650 USD

Нисък 445 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

139 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.